Literature DB >> 34085841

Metalloproteinases and their inhibitors are associated with pulmonary arterial stiffness and ventricular function in pediatric pulmonary hypertension.

Michal Schäfer1, D Dunbar Ivy1, Kathleen Nguyen2,3, Katie Boncella2,3, Benjamin S Frank1, Gareth J Morgan1, Kathleen Miller-Reed1, Uyen Truong4, Kelley Colvin2,3, Michael E Yeager2,3.   

Abstract

Disturbed balance between matrix metalloproteinases (MMPs) and their respective tissue inhibitors (TIMPs) is a well-recognized pathophysiological component of pulmonary arterial hypertension (PAH). Both classes of proteinases have been associated with clinical outcomes as well as with specific pathological features of ventricular dysfunction and pulmonary arterial remodeling. The purpose of this study was to evaluate the circulating levels of MMPs and TIMPs in children with PAH undergoing the same-day cardiac magnetic resonance imaging (MRI) and right heart catheterization. Children with PAH (n = 21) underwent a same-day catheterization, comprehensive cardiac MRI evaluation, and blood sample collection for proteomic analysis. Correlative analysis was performed between protein levels and 1) standard PAH indices from catheterization, 2) cardiac MRI hemodynamics, and 3) pulmonary arterial stiffness. MMP-8 was significantly associated with the right ventricular end-diastolic volume (R = 0.45, P = 0.04). MMP-9 levels were significantly associated with stroke volume (R = -0.49, P = 0.03) and pulmonary vascular resistance (R = 0.49, P = 0.03). MMP-9 was further associated with main pulmonary arterial stiffness evaluated by relative area change (R = -0.79, P < 0.01).TIMP-2 and TIMP-4 levels were further associated with the right pulmonary artery pulse wave velocity (R = 0.51, P = 0.03) and backward compression wave (R = 0.52, P = 0.02), respectively. MMPs and TIMPs warrant further clinically prognostic evaluation in conjunction with the conventional cardiac MRI hemodynamic indices.NEW & NOTEWORTHY Metalloproteinases have been associated with clinical outcomes in pulmonary hypertension and with specific pathological features of ventricular dysfunction and pulmonary arterial remodeling. In this study, we demonstrated that plasma circulating levels of metalloproteinases and their inhibitors are associated with standard cardiac MRI hemodynamic indices and with the markers of proximal pulmonary arterial stiffness. Particularly, MMP-9 and TIMP-2 were associated with several different markers of pulmonary arterial stiffness. These findings suggest the interplay between the extracellular matrix (ECM) remodeling and overall hemodynamic status in children with PAH might be assessed using the peripheral circulating MMP and TIMP levels.

Entities:  

Keywords:  metalloproteinases; pediatrics; pulmonary hypertension; stiffness

Mesh:

Substances:

Year:  2021        PMID: 34085841      PMCID: PMC8424580          DOI: 10.1152/ajpheart.00750.2020

Source DB:  PubMed          Journal:  Am J Physiol Heart Circ Physiol        ISSN: 0363-6135            Impact factor:   5.125


  44 in total

1.  Forward and backward running waves in the arteries: analysis using the method of characteristics.

Authors:  K H Parker; C J Jones
Journal:  J Biomech Eng       Date:  1990-08       Impact factor: 2.097

2.  Changes in the structure-function relationship of elastin and its impact on the proximal pulmonary arterial mechanics of hypertensive calves.

Authors:  Steven R Lammers; Phil H Kao; H Jerry Qi; Kendall Hunter; Craig Lanning; Joseph Albietz; Stephen Hofmeister; Robert Mecham; Kurt R Stenmark; Robin Shandas
Journal:  Am J Physiol Heart Circ Physiol       Date:  2008-07-25       Impact factor: 4.733

3.  Clinical features of paediatric pulmonary hypertension: a registry study.

Authors:  Rolf M F Berger; Maurice Beghetti; Tilman Humpl; Gary E Raskob; D Dunbar Ivy; Zhi-Cheng Jing; Damien Bonnet; Ingram Schulze-Neick; Robyn J Barst
Journal:  Lancet       Date:  2012-01-11       Impact factor: 79.321

Review 4.  Pediatric pulmonary hypertension.

Authors:  D Dunbar Ivy; Steven H Abman; Robyn J Barst; Rolf M F Berger; Damien Bonnet; Thomas R Fleming; Sheila G Haworth; J Usha Raj; Erika B Rosenzweig; Ingram Schulze Neick; Robin H Steinhorn; Maurice Beghetti
Journal:  J Am Coll Cardiol       Date:  2013-12-24       Impact factor: 24.094

5.  Metalloproteinase inhibition by Batimastat attenuates pulmonary hypertension in chronically hypoxic rats.

Authors:  Jan Herget; Jana Novotna; Jana Bibova; Viera Povysilova; Marie Vankova; Vaclav Hampl
Journal:  Am J Physiol Lung Cell Mol Physiol       Date:  2003-03-28       Impact factor: 5.464

6.  Pulmonary vascular input impedance is a combined measure of pulmonary vascular resistance and stiffness and predicts clinical outcomes better than pulmonary vascular resistance alone in pediatric patients with pulmonary hypertension.

Authors:  Kendall S Hunter; Po-Feng Lee; Craig J Lanning; D Dunbar Ivy; K Scott Kirby; Lori R Claussen; K Chen Chan; Robin Shandas
Journal:  Am Heart J       Date:  2007-09-27       Impact factor: 4.749

7.  Cardiac catheterization in children with pulmonary hypertensive vascular disease: consensus statement from the Pulmonary Vascular Research Institute, Pediatric and Congenital Heart Disease Task Forces.

Authors:  Maria Jesus Del Cerro; Shahin Moledina; Sheila G Haworth; Dunbar Ivy; Maha Al Dabbagh; Hanaa Banjar; Gabriel Diaz; Alexandria Heath-Freudenthal; Ahmed Nasser Galal; Tilman Humpl; Snehal Kulkarni; Antonio Lopes; Ana Olga Mocumbi; G D Puri; Beyra Rossouw; S Harikrishnan; Anita Saxena; Patience Udo; Lina Caicedo; Omar Tamimi; Ian Adatia
Journal:  Pulm Circ       Date:  2016-03       Impact factor: 3.017

8.  Noninvasive pulmonary artery wave intensity analysis in pulmonary hypertension.

Authors:  Michael A Quail; Daniel S Knight; Jennifer A Steeden; Liesbeth Taelman; Shahin Moledina; Andrew M Taylor; Patrick Segers; Gerry J Coghlan; Vivek Muthurangu
Journal:  Am J Physiol Heart Circ Physiol       Date:  2015-02-06       Impact factor: 4.733

9.  A machine learning cardiac magnetic resonance approach to extract disease features and automate pulmonary arterial hypertension diagnosis.

Authors:  Andrew J Swift; Haiping Lu; Johanna Uthoff; Pankaj Garg; Marcella Cogliano; Jonathan Taylor; Peter Metherall; Shuo Zhou; Christopher S Johns; Samer Alabed; Robin A Condliffe; Allan Lawrie; Jim M Wild; David G Kiely
Journal:  Eur Heart J Cardiovasc Imaging       Date:  2021-01-22       Impact factor: 6.875

10.  LGE patterns in pulmonary hypertension do not impact overall mortality.

Authors:  Andrew J Swift; Smitha Rajaram; Dave Capener; Charlie Elliot; Robin Condliffe; Jim M Wild; David G Kiely
Journal:  JACC Cardiovasc Imaging       Date:  2014-10-31
View more
  2 in total

1.  The role of matrix metalloproteinases in patients with pulmonary hypertension: data from a prospective study.

Authors:  Adriana Marc; Calin Pop; Adela-Viviana Sitar-Taut; Liviuta Budisan; Ioana Berindan-Neagoe; Dana Pop
Journal:  BMC Cardiovasc Disord       Date:  2021-12-20       Impact factor: 2.298

2.  Matrix Metalloproteinase-8 in Pulmonary Hypertension: The Sheep in the Wolf's Skin?

Authors:  Elena A Goncharova; Tatiana V Kudryashova; Giovanni Maroli; Soni S Pullamsetti
Journal:  Am J Respir Crit Care Med       Date:  2021-12-15       Impact factor: 21.405

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.